patrick.net
An Antidote to Corporate Media
1,189,968 comments by 13,851 users - Al_Sharpton_for_President, anniecoyote, RC2006 online now
invite responseComments 1 - 5 of 5 Search these comments
1
Blue
2021 Oct 5, 2:44pm
India is poor and cannot afford expensive fake. Chief minister Mr.Yogi from from a right wing party used old inexpensive and working solution.
2
Al_Sharpton_for_President
2021 Oct 6, 11:38am
Al_Sharpton_for_President
2021 Oct 6, 11:38am
Safety and efficacy of a MEURI Program for the use of high dose ivermectin in COVID-19 patients
Mayer, Marcos Alejandro; Krolewiecki, Alejandro; Ferrero, Alejandro; Bocchio, Marcelo; Barbero, Juan; Miguel, Marcos; Paladini, Ariel; Delgado, Carlos; Ojeda, Juan Ramón; Elorza, Claudia; Bertone, Ana; Fleitas, Pedro Emanuel; Vera, Gustavo; Kohan, Mario Rubén
Background
In the absence of antiviral alternatives, interventions under research for COVID-19 might be offered following guidelines from WHO for monitored emergency use of unregistered and experimental interventions (MEURI). Ivermectin is among several drugs explored for its role against SARS-CoV-2, with a well-known safety profile but conflicting data regarding clinical utility for COVID-19. The aim of this report is to inform on the results of a MEURI Program of high-dose ivermectin in COVID-19 carried out by the Ministry of Health of the Province of La Pampa, Argentina.
Methods
COVID-19 subjects, within 5 days of symptoms onset were invited to participate in the program, which consisted in the administration of ivermectin 0.6 mg/kg/day for 5 days plus standard of care. Active pharmacosurveillance was performed for 21 days, and hepatic laboratory assessments were performed in a subset of patients. Frequency of Intensive Care Unit (ICU) admission and COVID-19-related mortality of subjects in the ivermectin intention to treat group were compared with that observed in inhabitants of the same province during the same period not participating in the program.
Results
From 21232 subjects with COVID-19, 3266 were offered and agreed to participate in the ivermectin program and 17966 did not and were considered as controls. A total of 567 participants reported 819 adverse events (AEs); 3.13% discontinued ivermectin due to adverse. ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024). Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
Conclusion
This report highlights the safety and possible efficacy of high dose ivermectin as a potentially useful intervention deserving public health-based consideration for COVID-19 patients.
https://zenodo.org/record/5525362#.YV3saC1h2v6
Mayer, Marcos Alejandro; Krolewiecki, Alejandro; Ferrero, Alejandro; Bocchio, Marcelo; Barbero, Juan; Miguel, Marcos; Paladini, Ariel; Delgado, Carlos; Ojeda, Juan Ramón; Elorza, Claudia; Bertone, Ana; Fleitas, Pedro Emanuel; Vera, Gustavo; Kohan, Mario Rubén
Background
In the absence of antiviral alternatives, interventions under research for COVID-19 might be offered following guidelines from WHO for monitored emergency use of unregistered and experimental interventions (MEURI). Ivermectin is among several drugs explored for its role against SARS-CoV-2, with a well-known safety profile but conflicting data regarding clinical utility for COVID-19. The aim of this report is to inform on the results of a MEURI Program of high-dose ivermectin in COVID-19 carried out by the Ministry of Health of the Province of La Pampa, Argentina.
Methods
COVID-19 subjects, within 5 days of symptoms onset were invited to participate in the program, which consisted in the administration of ivermectin 0.6 mg/kg/day for 5 days plus standard of care. Active pharmacosurveillance was performed for 21 days, and hepatic laboratory assessments were performed in a subset of patients. Frequency of Intensive Care Unit (ICU) admission and COVID-19-related mortality of subjects in the ivermectin intention to treat group were compared with that observed in inhabitants of the same province during the same period not participating in the program.
Results
From 21232 subjects with COVID-19, 3266 were offered and agreed to participate in the ivermectin program and 17966 did not and were considered as controls. A total of 567 participants reported 819 adverse events (AEs); 3.13% discontinued ivermectin due to adverse. ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024). Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
Conclusion
This report highlights the safety and possible efficacy of high dose ivermectin as a potentially useful intervention deserving public health-based consideration for COVID-19 patients.
https://zenodo.org/record/5525362#.YV3saC1h2v6
4
Patrick
2021 Oct 6, 2:30pm
Patrick
2021 Oct 6, 2:30pm
Al_Sharpton_for_President says
I was just reading about statistical t-tests.
p means "the probability that we got these results by chance" if I understand correctly.
To the probability that they got those results by chance is 0.5%, very low.
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
I was just reading about statistical t-tests.
p means "the probability that we got these results by chance" if I understand correctly.
To the probability that they got those results by chance is 0.5%, very low.
5
FarmersWon
2021 Oct 6, 4:18pm
FarmersWon
2021 Oct 6, 4:18pm
I think two things are working in Bharat's favor.
1) It suffered a lot and 5 million people died but pretty much everyone have anti bodies. The people who survived have strong immunity to begin with.
2) Bharat's vaccine is old style "dead virus" vaccine as far as I know. Here low tech helps Bharat as the advance technology is used to weaken not strengthen the immune system.
I am not too sure if "ivermectin" is cause of them better off compared to vaccine-crazy Israel,Singapore etc.
1) It suffered a lot and 5 million people died but pretty much everyone have anti bodies. The people who survived have strong immunity to begin with.
2) Bharat's vaccine is old style "dead virus" vaccine as far as I know. Here low tech helps Bharat as the advance technology is used to weaken not strengthen the immune system.
I am not too sure if "ivermectin" is cause of them better off compared to vaccine-crazy Israel,Singapore etc.
original link